| PEGylated chitosan for nonviral aerosol and mucosal delivery of the CRISPR/Cas9 system in vitro H Zhang, TF Bahamondez-Canas, Y Zhang, J Leal, HDC Smyth Molecular pharmaceutics 15 (11), 4814-4826, 2018 | 67 | 2018 |
| Current status of in vitro models and assays for susceptibility testing for wound biofilm infections TF Bahamondez-Canas, LA Heersema, HDC Smyth Biomedicines 7 (2), 34, 2019 | 64 | 2019 |
| Intranasal immunization with dry powder vaccines TF Bahamondez-Canas, Z Cui European journal of pharmaceutics and biopharmaceutics 122, 167-175, 2018 | 62 | 2018 |
| PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro TF Bahamondez-Canas, H Zhang, F Tewes, J Leal, HDC Smyth Molecular Pharmaceutics 15 (4), 1643-1652, 2018 | 44 | 2018 |
| Influence of Excipients on the Antimicrobial Activity of Tobramycin Against Pseudomonas aeruginosa Biofilms T Bahamondez-Canas, HDC Smyth Pharmaceutical research 35, 1-13, 2018 | 12 | 2018 |
| Efficacy of Ciprofloxacin and Its Copper Complex against Pseudomonas aeruginosa Biofilms F Tewes, TF Bahamondez-Canas, HDC Smyth Aaps Pharmscitech 20, 1-9, 2019 | 9 | 2019 |
| In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa F Tewes, TF Bahamondez-Canas, D Moraga-Espinoza, HDC Smyth, ... European Journal of Pharmaceutics and Biopharmaceutics 152, 210-217, 2020 | 7 | 2020 |
| Nuevas perspectivas para el tratamiento de la infección por Helicobacter pylori B Velasco, D Cynthia, TF Bahamondez-Canas Pontificia Universidad Católica De Chile, 2021 | 5 | 2021 |
| Development, characterization, and in vitro testing of Co-delivered antimicrobial dry powder formulation for the treatment of Pseudomonas aeruginosa biofilms TF Bahamondez-Canas, S Ferrati, DF Moraga-Espinoza, HDC Smyth Journal of Pharmaceutical Sciences 107 (8), 2172-2178, 2018 | 4 | 2018 |
| Nasal drug delivery AD Brunaugh, D Moraga-Espinoza, T Bahamondez-Canas, HDC Smyth, ... Essential Pharmaceutics, 215-220, 2024 | 3 | 2024 |
| Modified release solid oral dosage forms AD Brunaugh, D Moraga-Espinoza, T Bahamondez-Canas, HDC Smyth, ... Essential pharmaceutics, 73-89, 2024 | 3 | 2024 |
| The forgotten material: Highly dispersible and swellable gelatin-based microspheres for pulmonary drug delivery of cromolyn sodium and ipratropium bromide B Behrend-Keim, A Castro-Muñoz, L Monrreal-Ortega, B Ávalos-León, ... International Journal of Pharmaceutics 644, 123331, 2023 | 3 | 2023 |
| Ophthalmic and otic drug delivery AD Brunaugh, D Moraga-Espinoza, T Bahamondez-Canas, HDC Smyth, ... Essential Pharmaceutics, 141-149, 2024 | 2 | 2024 |
| Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process J Gallegos-Catalán, Z Warnken, TF Bahamondez-Canas, ... Pharmaceutics 13 (7), 1051, 2021 | 2 | 2021 |
| Essential Pharmaceutics in the Flipped Classroom AD Brunaugh, D Moraga-Espinoza, T Bahamondez-Canas, HDC Smyth, ... Essential Pharmaceutics, 1-11, 2024 | 1 | 2024 |
| Capsule and Tablet Dosage Forms AD Brunaugh, D Moraga-Espinoza, T Bahamondez-Canas, HDC Smyth, ... Essential Pharmaceutics, 47-72, 2024 | 1 | 2024 |
| Disperse Systems: Suspensions AD Brunaugh, D Moraga-Espinoza, T Bahamondez-Canas, HDC Smyth, ... Essential Pharmaceutics, 109-129, 2024 | 1 | 2024 |
| A critical perspective on future developments based on the knowledge we have now TF Bahamondez-Canas, J Leal, HDC Smyth Inhalation Aerosols, 389-396, 2019 | 1 | 2019 |
| Antibiofilm formulations and use thereof HDC Smyth, TF Bahamondez-Canas, F Tewes, LA Heersema | 1 | 2018 |
| Drug delivery strategies to treat Pseudomonas aeruginosa biofilm infections TF Bahamondez-Canas | 1 | 2018 |
Daniel F Moraga-EspinozaThe University of Texas at Austin; Universidad de ValparaísoVerified email at utexas.edu
